JAV Javelin Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Javelin Pharmaceuticals Inc. (AMEX:JAV).  The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

Our trade alerts and ideas are provided free to investors.  Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.

The full report is available at: http://www.microstockprofit.com/lp/JAV

JAV is trading above its upper Bollinger Band.  Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

Javelin Pharmaceuticals Inc. (JAV) is a specialty pharmaceutical company engaged in the research, development and commercialization of products for the pain management market.  The Company develops products optimized for relieving acute moderate-to-severe pain. In addition, the product choices available for the treatment of acute moderate-to-severe pain are limited in the doses that may be given due to side effects, including cardiovascular depression, tolerance and addiction, respiratory depression, constipation, sedation and general diminution of quality of life. JAV's product candidates Dyloject (injectable diclofenac), Ereska (intranasal ketamine) and Rylomine (intranasal morphine) are focused on treating a variety of pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain, such as orthopedic injury pain, procedural pain and burn pain.

Message Board Search for JAV: http://www.boardcentral.com/boards/JAV

In the report, the analyst notes:

"Hospira (NYSE:HSP) earlier this week announced its plans to complete the tender offer by Discus Acquisition Corp., a wholly owned Hospira subsidiary, for all of JAV's outstanding shares of common stock at the end of day on June 30, 2010. Hospira agreed to acquire JAV in April, in a deal valuing the latter at $2.20 per share in cash, or approximately $145 million.

"Hospira anticipates JAV to meet all of the conditions mentioned in the tender offer at the end of the scheduled expiration and plans to pay for all of JAV common stock validly tendered and not withdrawn before the expiration of the offer."

To read the entire report visit: http://www.microstockprofit.com/lp/JAV

See what investors are saying about JAV at penny stock forum

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities.  MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC.  Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication.  Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT:  MicroStockProfit.com
          Brian Johnson
          1-888-307-2850
          info@microstockprofit.com